ZA201603118B - Compounds for use in prevention and treatment of neurodegenerative diseases and pain - Google Patents

Compounds for use in prevention and treatment of neurodegenerative diseases and pain

Info

Publication number
ZA201603118B
ZA201603118B ZA2016/03118A ZA201603118A ZA201603118B ZA 201603118 B ZA201603118 B ZA 201603118B ZA 2016/03118 A ZA2016/03118 A ZA 2016/03118A ZA 201603118 A ZA201603118 A ZA 201603118A ZA 201603118 B ZA201603118 B ZA 201603118B
Authority
ZA
South Africa
Prior art keywords
pain
prevention
compounds
treatment
neurodegenerative diseases
Prior art date
Application number
ZA2016/03118A
Other languages
English (en)
Inventor
Jim-Min Fang
Yun-Lian Lin
Jung-Hsin Lin
Chun-Jung Lin
Yijuang Chern
Nai-Kuei Huang
Hung-Li Wang
Benjamin Pang-Hsien Tu
Chih-Cheng Chen
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of ZA201603118B publication Critical patent/ZA201603118B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
ZA2016/03118A 2013-10-23 2016-05-10 Compounds for use in prevention and treatment of neurodegenerative diseases and pain ZA201603118B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361894699P 2013-10-23 2013-10-23
PCT/US2014/061734 WO2015061426A1 (en) 2013-10-23 2014-10-22 Compounds for use in prevention and treatment of neurodegenerative diseases and pain

Publications (1)

Publication Number Publication Date
ZA201603118B true ZA201603118B (en) 2019-04-24

Family

ID=52993493

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2016/03118A ZA201603118B (en) 2013-10-23 2016-05-10 Compounds for use in prevention and treatment of neurodegenerative diseases and pain

Country Status (14)

Country Link
US (1) US10301348B2 (enExample)
EP (1) EP3060566B1 (enExample)
JP (1) JP6534997B2 (enExample)
KR (1) KR102313314B1 (enExample)
CN (1) CN106414456B (enExample)
AU (1) AU2014340114B2 (enExample)
BR (1) BR112016008901B1 (enExample)
CA (1) CA2927699C (enExample)
IL (1) IL245103B (enExample)
MX (1) MX367707B (enExample)
RU (1) RU2695358C2 (enExample)
SG (1) SG11201603063WA (enExample)
WO (1) WO2015061426A1 (enExample)
ZA (1) ZA201603118B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201792261A1 (ru) * 2015-05-29 2018-04-30 Зе Боард Оф Трастис Оф Зе Лилэнд Стэнфорд Джуниор Юниверсити Нуклеозидные вещества для уменьшения вредной активности генов, содержащих удлиненные нуклеотидные повторы
US11753432B2 (en) 2017-01-27 2023-09-12 Academia Sinica Compound with analgesic effect for use in prevention and treatment of pain
CN119384282A (zh) * 2022-02-10 2025-01-28 周美吟 治疗脊髓损伤的方法及用于其中的组合物
CN119630406A (zh) * 2022-07-07 2025-03-14 周美吟 治疗思觉失调症的方法及用于其中的组合物
CN120548177A (zh) * 2022-12-29 2025-08-26 周美吟 治疗睡眠障碍的方法及用于其中的组合物
WO2024196760A1 (en) * 2023-03-17 2024-09-26 Academia Sinica Method of treating tuberous sclerosis complex or epilepsy and composition for use therein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003148A2 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Heteroaromatic derivatives of adenoside
US5034381A (en) * 1988-01-07 1991-07-23 Ciba-Geigy Corporation 2-(substituted amino) adenosines as antihypertensives
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
ES2095960T3 (es) * 1990-09-25 1997-03-01 Rhone Poulenc Rorer Int Compuestos que tienen propiedades antihipertensivas y antiisquemicas.
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
US20120295863A1 (en) 2009-11-13 2012-11-22 Yun-Lian Lin Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases
CN102812033B (zh) * 2009-12-10 2015-11-25 中国医学科学院药物研究所 N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途
JP6208693B2 (ja) 2012-02-09 2017-10-04 ブランドバンプス,エルエルシー 改良されたグリップを有する装飾された検知可能な警告パネル
WO2013120078A1 (en) * 2012-02-11 2013-08-15 Academia Sinica Methods and compositions for treating pain

Also Published As

Publication number Publication date
MX2016005174A (es) 2016-08-11
BR112016008901B1 (pt) 2022-08-23
US10301348B2 (en) 2019-05-28
AU2014340114B2 (en) 2018-10-18
NZ719740A (en) 2021-02-26
CA2927699A1 (en) 2015-04-30
EP3060566A4 (en) 2017-06-14
JP2016535019A (ja) 2016-11-10
WO2015061426A1 (en) 2015-04-30
RU2016118282A (ru) 2017-11-28
EP3060566A1 (en) 2016-08-31
RU2016118282A3 (enExample) 2018-06-18
CN106414456A (zh) 2017-02-15
CN106414456B (zh) 2018-12-14
CA2927699C (en) 2022-07-05
BR112016008901A2 (pt) 2020-05-12
US20160264613A1 (en) 2016-09-15
RU2695358C2 (ru) 2019-07-23
IL245103B (en) 2019-02-28
IL245103A0 (en) 2016-06-30
KR20160086852A (ko) 2016-07-20
AU2014340114A1 (en) 2016-05-26
MX367707B (es) 2019-09-03
EP3060566B1 (en) 2018-09-05
KR102313314B1 (ko) 2021-10-19
SG11201603063WA (en) 2016-05-30
JP6534997B2 (ja) 2019-06-26

Similar Documents

Publication Publication Date Title
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
PT3031826T (pt) Composição farmacêutica para o tratamento e/ou a prevenção do cancro
PT2991600T (pt) Micro-oclusões e métodos relacionados para o tratamento da pele
GB201320729D0 (en) Therapeutic compounds and their use
IL239735A0 (en) Treatment and diseases associated with toxic aldehyde
SG11201509012QA (en) Sobetirome in the treatment of myelination diseases
HUE038983T2 (hu) Apoptózist indukáló hatóanyagok rák, valamint immun- és autoimmunbetegségek kezelésére
IL239851B (en) Methods and compositions for treating diseases that act to remove myelin
EP2948195A4 (en) INCLUDED DEVICES FOR THE TREATMENT OF MEDICAL WASTE AND METHOD FOR THE USE THEREOF
GB201311361D0 (en) Compounds and their therapeutic use
IL245103A0 (en) Compounds for use in the prevention and treatment of degenerative nerve diseases and pain
IL246036A0 (en) A therapeutic and/or prophylactic substance containing a derivative of 1-indensulfamide for pain
ZA201603117B (en) Withanolides useful for the treatment of neurodegenerative diseases
ZA201501503B (en) Bio-inoculant and use thereof for treatment of effluents
SI3598971T1 (sl) Odmerne oblike in terapevtske uporabe L-4-klorokinurenina
EP3104869A4 (en) Treatment of pain
PL3074033T3 (pl) Związki do leczenia otyłości i sposoby ich zastosowania
GB201308736D0 (en) Compounds and their therapeutic use
ZA201506396B (en) Use of sedoheptulose for prevention or treatment of inflammation
IL259383A (en) A compound for use in the prevention and treatment of neurodegenerative diseases
SG11201505909WA (en) Treatment and prevention of acne
HUP1300454A2 (hu) Daganatos betegségek gyógyítására és megelõzésére alkalmas gyógyászati készítmények, és eljárás azok elõállítására
GB201317373D0 (en) Treatment and prevention of cancer
GB201309001D0 (en) Methods for prevention and treatment of preeclampsia
GB201317804D0 (en) Therapeutic compounds and their use